𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Optimizing First-Line Therapy for Patients With Chronic Myeloid Leukemia

✍ Scribed by Carmen Fava; Jorge Cortes

Book ID
117822135
Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
436 KB
Volume
46
Category
Article
ISSN
1532-8686

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

First-line therapy for chronic myeloid l
First-line therapy for chronic myeloid leukemia: Past, present, and future
✍ Carolina Pavlovsky; Hagop Kantarjian; Jorge E. Cortes πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 326 KB

## Abstract The development of Bcr‐Abl tyrosine kinase inhibitors has dramatically changed the prognosis of patients with newly diagnosed chronic myeloid leukemia (CML). Standard‐dose imatinib (400 mg/day in chronic phase, 600 mg/day in advanced CML) now dominates the management of this disease, pr

Philadelphia-negative acute myeloid leuk
Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia
✍ Carmen Fava; Jorge Cortes πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 306 KB πŸ‘ 2 views

## Induction of integrin b 1 expression in bone marrow cells after chemotherapy correlates with the overexpression of lung resistance protein and poor outcome in patients with multiple myeloma To the Editor: Acquired drug resistance continues to be one of the major obstacles hindering the successf